The Potential of Developing Pan-Coronaviral Antibodies to Spike Peptides in Convalescent COVID-19 Patients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.08.20.20178566: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Patient cohorts: All analyses of human materials were performed in accordance with the institutional guidelines and with the approval of the Ethics Committees of Danylo Halytsky Lviv National Medical University (DH LNMU No.5/2017–02–23).
Consent: Written informed consent was obtained from every person before blood collection.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Protein structures were visualized using PyMOL (https://pymol.org/). PyMOLsuggested: (PyMOL, RRID:SCR_000305)Multiple sequence alignments were done using CLUTALW … SciScore for 10.1101/2020.08.20.20178566: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Patient cohorts: All analyses of human materials were performed in accordance with the institutional guidelines and with the approval of the Ethics Committees of Danylo Halytsky Lviv National Medical University (DH LNMU No.5/2017–02–23).
Consent: Written informed consent was obtained from every person before blood collection.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Protein structures were visualized using PyMOL (https://pymol.org/). PyMOLsuggested: (PyMOL, RRID:SCR_000305)Multiple sequence alignments were done using CLUTALW [16] Data analysis: ELISA testing was performed in duplicate using 2 technical replicates for each analysis (coefficient of variation [CV] always < 3%). CLUTALWsuggested: NoneAll analyses were performed using Excel 2016 (Microsoft Corp., Redmond, WA, USA) and Prism 8.2 (GraphPad, San Diego, USA) software. Excelsuggested: NonePrismsuggested: (PRISM, RRID:SCR_005375)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
